Document:

<PAGE>

                                                                    EXHIBIT 10.2

                              DEVELOPMENT AGREEMENT

THIS DEVELOPMENT AGREEMENT is dated January 1, 2003

BETWEEN:

            GLOBE LABORATORIES INC., a British Columbia Corporation having its
            registered and records office at 410 - 1333 West Broadway,
            Vancouver, B.C. V6H 4C1

                                                (hereinafter called "Developer")

AND:

            CHEMOKINE THERAPEUTICS CORP., a Delaware Corporation having a
            registered and records office at 801 South Figueroa Street, 14th
            Floor, Los Angeles California 90017

                                                    (hereafter called "Client").

WHEREAS:

A Developer is an independent biotechnology research and development corporation
with its principal offices and research facilities in the Province of British
Columbia, Canada;

B Client wishes to engage Developer to provide biotechnology research and
development on NOVEL peptides and large scale therapeutic peptides as more
particularly set forth in Schedule A on the terms and conditions contained
herein;

      NOW, THEREFORE, in consideration of the premises and mutual covenants
contained herein and other good and valuable consideration (the receipt and
sufficiency of which are hereby acknowledged), the parties hereto agree as
follows:

1.    INTERPRETATION

Definitions. In this Agreement, the following terms have the following meanings.

      (a) " Affiliate" shall mean any corporation or other business entity
      controlled by, controlling, or under common control with Client or
      Developer. For this purpose "control" means (i) direct or indirect
      beneficial ownership of at least fifty percent (50%) of the voting stock
      of a corporation; or (ii) the power to direct or cause the direction of
      the management and policies of such corporation or other business entity,
      whether by contract, agreement, resolution, regulation or otherwise.

      (b) "Agreement" means this Development Agreement and all schedules
      attached hereto as the same and may be amended from time to time in
      accordance with the provisions hereof and the terms "hereof", hereunder,
      "hereto", and similar expressions refer to this Agreement and not to any
      particular section.

      (c) "Business Day" means any day other than a Saturday, Sunday or days in
      which banks in Vancouver, British Columbia are not open for business.

      (d) "Confidential Information" shall mean any scientific, technical, trade
      or business information given to a Party (the "Recipient") by the other
      Party (the "Disclosers"), including, without limitation, Technologies
      (defined below), formulations, techniques, methodologies, assay systems,
      formulae, procedures, tests, equipment, data, reports, know-how,
      inventions whether patentable or not, sources of supply, patent
      positioning, relationship with consultants and employees, business plans

                                                                               1

<PAGE>

      and business developments, information concerning the existence, scope or
      activities of any research development, manufacturing, marketing or other
      projects of the Discloser, and any other confidential information about or
      belonging to Discloser's suppliers, licensors, licensees, partners,
      affiliates, customers, potential customers or other Confidential
      Information, however, shall not include any information that:

            (i) is or becomes publicly available through no fault of Recipient;

            (ii) is already in the rightful possession of Recipient prior to its
            receipt, as shown by prior written records or other probative
            evidence;

            (iii) is disclosed by Recipient pursuant to court order, a
            requirement of law, regulation or the order of an administrative
            authority, provided the Recipient, to the fullest extent permitted
            or reasonably feasible under the circumstances, shall have secured
            confidential treatment of the information disclosed.

      (e) "Monthly Charges" means Developer's monthly charges for the Services
      to be provided hereunder, as further defined in section 3.1.

      (f) "Parties" means, together, Developer and Client and "Party" means
      either one of them.

      (g) "Person" includes any individual, corporation, partnership, Limited
      Liability Company, joint venture, association, joint stock company, trust,
      unincorporated organization or any other entity.

      (h) "Services" has the meaning ascribed thereto in section 2.

      (i) "Technologies" include, without limitation, proteins, peptides, amino
      acids, genes, DNA and RNA sequences, plasmids, vectors, expression
      systems, cells, cell lines, chemical reactions, peptide sequencing,
      peptide synthesis, biological substances, derivatives or replications
      thereof or therefrom, together with all reagents, chemical compounds or
      other materials.

      (j) "Third Party" means any Person other than Developer or Client.

      (k) "Work Product" means the Technologies and any data, information
      materials, equipment, formulation, test procedures or quality control
      requirements related thereto.

1.2 Number and Gender. This Agreement shall be read with all changes in number
and gender as are required by the context.

1.3 Currency. All dollar amounts in this Agreement are in United\ States
Currency unless otherwise specified.

1.4 Headings. The headings in this Agreement are inserted for convenience of
reference only and shall not affect the interpretation of this Agreement.

1.5 Governing Law. This Agreement shall be governed by and construed in
accordance with the Laws of the Province of British Columbia.

1.6 Generally Accepted Accounting Principles. In this Agreement, except to the
extent otherwise expressly provided, references to "GAP" means generally
accepted accounting practices.

                                                                               2

<PAGE>

1.7 Schedules. The following are the schedules attached to and forming a part of
this Agreement: Schedule A.

2.    SERVICES AND OWNERSHIP

2.1 General Services. In consideration of the fees described in section 3 of
this Agreement, Developer will provide to the Client research and development
services including any patents and all other services related to the project
outlined in Schedule A (attached). Developer will provide the services as
outlined in Schedule A and other materials related to the treatment of diseases
by the products specified in Schedule A from the generation stage to the
completed, ready-to-market stage, and as more particularly described in Schedule
A, attached hereto (collectively, the "Services").

2.2 Obligations. Developer shall carry out the Services in a good, workmanlike
manner at all times. Developer and the Client agree to work together to develop
completion schedules for each development project identified and requested by
Client. Developer shall use its best efforts to meet the timelines and
milestones for development of each project identified by Client.

2.3 Reporting. Developer will provide Client reports on the progress of each
project in the form of reports and other documentation agreed to between Client
and Developer immediately following execution of this Agreement.

2.4 Ownership of Work Product. The Developer acknowledges that all proprietary
interest including all patent rights, trademarks, copyright, trade secrets and
Confidential Information in and to any Work Product contained in Schedule A
shall be the sole and exclusive property of the Client. The Developer hereby
assigns to the Client all such rights that it possesses or may possess in the
field as per Schedule A. Developer agrees to sign, or to cause its employees or
others who may provide pursuant to the terms hereof any assistance, in respect
of the Services to confirm such ownership. The Developer will ensure that the
Client is provided with all documentation and research results in respect of the
Technologies as well as with copies of all working papers, notes, and memoranda
that made or obtained in connection Services, or at such earlier time as the
Client may request.

2.5 Waiver of Moral Rights. The Developer agrees that it will use its best
efforts to ensure that any employee or any other Person who is to contribute to
the Work Product hereunder shall, irrevocably waive in writing, any and all
moral rights arising under the Copyright Act (Canada), as amended, the laws of
the Province British Columbia or applicable jurisdictions or at common law that
such individual, as author, has with respect to any copyrighted works prepared
by such individual, as author, has with respect to any copyrighted works
prepared by such individual hereunder, including, without limitation, the right
to attribution of authorship, the bright to restrain any distortion or
modification of any such work and the right to prohibit any use of such,
copyrighted work, in association with a product, services, cause or institution
that might be prejudicial to such individual's honor or reputation.

2.6 Cooperation by Developer. Should Client seek to obtain registered patent,
trademark or copyright protection in any country in the world in respect of the
Work Product, Developer agrees to cooperate fully without compensation and
assure that any employee or other Person who contributes to Work Product
Cooperates in providing information, completing forms or certificates or
performing actions and obtaining the necessary signatures or assignments
required to obtain such patent, trademark or copyright registration. In the
event Client is unable for any reason to obtain Developer's signature on any
document necessary for any purpose set forth in the foregoing sentence,
Developer hereby irrevocably designates and appoints Client and its duly
authorized officers and agents as Developer's agent with full power of attorney
to act for and on the Developer's behalf to execute and file any such document
or certificate with the same force and effect as if executed by Developer.

                                                                               3

<PAGE>

3.    DEVELOPMENT FEES AND PAYMENT

3.1 Monthly Charges. In consideration of the Services provided by Developer
hereunder, Client agrees to pay to Developer all the costs of such research and
development including administrative and other overhead costs (the "Costs"), as
determined in accordance with GAAP, plus a margin of two percent (2%) of such
Costs ("Margin") (all the foregoing together, the "Monthly Charges").

3.2 Payment. Client agrees to pay the Monthly Charges as is invoiced by the
Developer to the Client and any other charges payable hereunder and that are
properly included in an invoice within 30 days of the date of such invoice. Each
invoice will state separately all applicable taxes owing by Client, if any.

3.3 Margin Adjustment. The parties agree that they will, on a quarterly basis,
review the Margin charged by Developer to Client and, if the parties mutually
agree in writing, the Margin will be amended for the month immediately following
such mutual agreement.

4.    TERM AND TERMINATION

4.1 Term. The Term of this Agreement shall commence on the date of this
agreement and continue for one (1) year. The Term shall automatically renew
unless terminated pursuant to section 4.2 or unless either party delivers to the
other party three months written notice prior to the expiry of the Term that
they intend not to renew.

4.2 Termination. This Agreement may be terminated by mutual agreement of the
Parties or by either Party on breach by the other Party of the terms hereof
provided such breach remains uncured 10 Business Days following notice by the
non-breaching Party specifying the breach.

4.3 Obligation on Termination. Upon termination of this Agreement for any
reason, the Developer shall return all Confidential Information, Work Product
and work-in-process as well as all notes, writings, documents and other
materials related to the Work Product. The Parties shall have no further
obligations pursuant to the terms of this Agreement except as provided for in
section 5.1.

5.    GENERAL

5.1.1 Confidentiality. It will be necessary of the Parties to disclose to each
of other Confidential Information that will assist the Parties in successfully
carrying out the objectives of this Agreement. Developer, or Client, as the case
may be, during the life of the Agreement and for a period of five (5) years
after the termination of this Agreement, shall not disclose the other's
Confidential Information or Technologies to any Third Party except an Affiliate
who requires such information to carry out the objectives of this Agreement.
Each Party shall use the same degree of care as exercised with respect to their
own Confidential Information to prevent the disclosure of the Confidential
Information to any Third party and shall not use the Confidential Information
for any purpose other than exercising any rights granted to it herein. Developer
agrees to indemnify and save Client and its directors, officers and employees
(the "Client Representatives") harmless from and against any and all damages
that Client or the Client Representatives may suffer or incur as a result of any
breach by Developer or any director, officer, employee, agent or representative
of Developer (the "Developer Representatives") of this section 5.1. Client
agrees to indemnify and save Developer and the Client Representatives harmless
from and against any and all damages that Developer or the Developer
Representatives may suffer or incur as a result of any breach by Client or any
Developer Representatives of this section 5.1.

                                                                               4

<PAGE>

5.2 The Developer acknowledges that any breach of this Agreement may cause
irreparable harm to Client and agrees that Client's remedies for any breach may
include, in addition to damages and other available remedies against the
Developer or any of its affiliates, injunctive relief against such breach. The
Developer agrees that Client shall be entitled to an award of its reasonable
attorney's fees if it prevails in any action to enforce this Agreement.

5.3 Agreement Not Transferable. Developer may not assign this Agreement or any
rights or obligations hereunder, nor subcontract any such obligations without
the prior written consent of Client.

5.4 Entire Agreement. This Agreement constitutes the entire agreement between
the Parties pertaining to the subject matter of this Agreement. There are no
warranties, representations or agreements between the Parties in connection with
such subject matter except as specifically set forth in this Agreement.

5.5 Amendment/Waiver. No amendment of this Agreement, or waiver of any rights
pursuant to this Agreement, shall be binding unless executed in writing by the
Parties hereto. No waiver of any provision of this agreement shall constitute a
waiver of any other provision nor shall any waiver of any provision of this
Agreement constitute waiver unless otherwise expressly provided.

5.6 Notices. Any notice or other communication required or permitted to be given
hereunder shall be in writing and shall be given by facsimile transmission or by
hand delivery as provided for in this section. Any such notice or other
communication, if sent by facsimile or hand delivered, shall be deemed to have
been received on the Business Day following the date of transmission or delivery
to the applicable address set forth below. Notice of change of address shall
also be governed by this section. Notices and other communications shall be
addressed as follows:

If to Client:

      Chemokine Therapeutics Corp.
      801 South Figueroa Street, 14th Floor,
      Los Angeles California 90017

      Attention: Russell Frandsen, Corporate Attorney

If to Developer:

      Globe Laboratories Inc.
      2386 East Mall, Unit 204
      Vancouver, BC V6T Z3

      Attention: Dr. Ahmed Merzouk

5.7 Further Assurance. Each of the Parties shall execute and deliver all such
further agreements, documents, instruments and certificates and do such further
acts and things as may be reasonably required to give effect to this Agreement.

5.8 Independent Contractor. Developer is and shall at all times be an
independent contractor and shall not be deemed to be an agent, partner or joint
venture of or with Client. Nothing in this Agreement shall be construed to
restrict the Developer from engaging in other research and development projects
provided that Developer takes reasonable steps to protect the Confidential
Information of the Client as provided for herein.

5.9 Binding Effect. This Agreement will ensure to the benefit of and be binding
upon the Parties hereto and their respective successors, heirs and legal
personal representatives.

                                                                               5

<PAGE>

IN WITNESS WHEREOF the Parties hereto have executed this Agreement on the day
and year first above written.

Chemokine Therapeutics Corp.
Per:

______________________________________________
Dr. Hassan Salari, President & CEO

Globe Laboratories Inc.
Per:

______________________________________________
Dr. Ahmed Merzouk, Director of Operations

                                                                               6

<PAGE>

                                   SCHEDULE A

                                    Services

The services to be provided by Developer to Client will include the following
specific services and responsibilities:

1     Design of chemokine analogs based on peptides structures.

2     Testing of newly designed chemokine analogs against chemokine receptors
      (receptor competition binding studies, calcium responses and chemotaxis).

3     Testing of newly designed chemokine analogs in animal models of the
      diseases.

4     Development of large scale chemokine analogs production by synthetic
      routes.

5     Production of grams quantity of chemokine analogs under good laboratory
      practices (GLP).

6     Feasibility studies in determining large scale production of chemokine
      analogs under GMP production for human use.

7     Filling results of the research for patent on behalf of the Client.

8     Assisting Client in preparation of scientific reports for publications and
      presentations in academic organizations.

9     Assisting Client in filing drug master file (DMF) with FDA.

10    Participation with Client in defending the research work in meetings with
      potential investors.

                                                                               7<PAGE>

                                                                    EXHIBIT 10.3

                              EMPLOYMENT AGREEMENT

      THIS EMPLOYMENT AGREEMENT is made this 1st day of April 2004 (the
"Agreement"), between Chemokine Therapeutics Corp. a Delaware Corporation and
its wholly owned subsidiary Chemokine Therapeutics (BC) Corp. a BC Corporation
(collectively the "Company"), and Dr. Hassan Salari (the "Employee or the
Executive").

RECITALS

      A.    Employee is engaged in the business (the "Business" or the
            "Employee's Business") of research and development of therapeutic
            products based on the biology of chemokines.

      B.    Company desires to engage the services of Employee as its Chairman,
            President and Chief Executive Officer ("CEO") and Employee is
            willing to agree to these terms.

      C.    Employee desires to obtain the compensation and, bonus opportunity
            and other benefits provided for in this Agreement.

AGREEMENT

NOW, THEREFORE, in consideration of the mutual covenants herein contained, and
other good and valuable consideration, the sufficiency and receipt of which are
hereby acknowledged, the parties agree as follows:

      1.    ENGAGEMENT. The Company hereby engages the Executive, and the
            Executive agrees to be engaged as Chairman, President and CEO.
            Changes may be made from time to time by the Company in its sole
            discretion to the duties, reporting relationships and title of
            Executive, in which will require the Executive' full consent.
            Executive will devote full time and attention to achieving the
            purposes and discharging the responsibilities as may be described
            from time to time by the Board of Directors of the Company.
            Executive will comply with all rules, policies and procedures of
            Company as modified from time to time, including without limitation,
            rules and procedures set forth in any Executive handbook,
            supervisor's manuals and operating manuals as may be adopted by the
            Company from time to time. Executive will perform all of Executive's
            responsibilities and will ensure that his work are in compliance
            with applicable laws.

      2.    TERM OF ENGAGEMENT. The term of engagement will be for the five-year
            period commencing on April 1, 2004 and ending April 01, 2009 ("the
            Term"), unless sooner terminated in accordance with the terms and
            conditions of this Agreement. Thereafter, unless terminated in
            writing, Executive's engagement under this Agreement will
            automatically renew for an additional term, subject to the terms and
            conditions of this

                                                                               1

<PAGE>

            Agreement. Notwithstanding those periods, this Agreement will remain
            enforceable and in effect until all the parties' rights and
            obligations have been satisfied, terminated or have expired, as
            provided herein. For the purpose of this agreement each term is five
            (5) years.

      3.    COMPENSATION. For the duration of Executive's engagement hereunder,
            the Executive will be entitled to compensation, which will be
            computed and paid pursuant to the following subparagraphs.

            3.1   CASH COMPENSATION. Executive will be financially compensated
                  by way of monthly salary. The Company agrees to pay Executive
                  Two Hundred Fifty Thousand Dollars ($250,000) per year until
                  the termination of this Agreement. Executive's financial
                  compensation could be adjusted from time to time as per other
                  senior employees of the Company. At no time the base
                  compensation package could be reduced regardless of the change
                  of Executive's title and duties. The Executive has the right
                  to choose the method of cash compensation at its sole
                  discretion.

            3.2   STOCK OPTIONS. Executive shall be entitled to participate in
                  any stock option, stock bonus, phantom stock right, or other
                  such plans or arrangements, which may exist during the term of
                  his engagement, provided that Executive's entitlement will
                  depends on the terms of any such arrangement or plan. At no
                  time the Executive's stock option package can be less than the
                  highest senior employees of the Company, regardless of the
                  Executive's change of title and duties.

      4.    OTHER BENEFITS; BUSINESS EXPENSES.

            4.1   CERTAIN BENEFITS. Executive will be eligible to participate in
                  all Executive benefit programs established by Company that are
                  applicable to management personnel on his choice, on a basis
                  commensurate with Executive's position and in accordance with
                  Company's policies from time to time, but nothing herein shall
                  require the adoption or maintenance of any such plan.

            4.2   VACATIONS, HOLIDAYS AND EXPENSES. For the duration of
                  Executive's engagement hereunder, Executive will be provided
                  such holidays, sick leaves and vacation as Company makes
                  available to its management level Executives generally.
                  Company will reimburse Executive in accordance with company
                  policies and procedures for reasonable expenses necessarily
                  incurred in the performance of duties hereunder against
                  appropriate receipts and vouchers indicating the specific
                  business purpose for each such expenditure.

                                                                               2

<PAGE>

      5.    TERMINATION OR DISCHARGE BY COMPANY.

            5.1   FOR CAUSE. Company will have the right to immediately
                  terminate Executive's services and this Agreement for cause.
                  "Cause" means: any material breach of this Agreement by
                  Executive, including, without limitation, breach of
                  Executive's covenants in Sections 8 and 9 or conviction of a
                  felony or failure to contest prosecution for a felony. Upon
                  termination of Executive's engagement hereunder for cause,
                  Executive will have no right on any unvested benefits or any
                  other compensation or payments after the termination date. In
                  the event of termination due to death or disability of
                  Executive, Executive's family will have the right to any
                  unvested benefits or any other compensation or payments after
                  the last day or the month in which Executive's death or
                  disability occurred. For purposes of this Agreement,
                  "disability" means the incapacity or inability of Executive,
                  whether due to accident, sickness or otherwise, as determined
                  by a medical doctor and confirmed in writing by such doctor,
                  to perform the essential functions of Executive's position
                  under this Agreement, without reasonable accommodation
                  (provided that no accommodation that imposes undue hardship on
                  Company will be required) for an aggregate for ninety (90)
                  days during any period of one hundred eighty (180) consecutive
                  days.

            5.2   WITHOUT CAUSE. Company may terminate Executive's engagement
                  under this Agreement without cause and without advance notice;
                  provided, however, that Company will pay the Executive the
                  amount of Five Hundred Thousand Dollars (US$500,000). In
                  addition, Company will, within thirty (30) calendar days after
                  Executive's termination by Company under this Section 5.2, pay
                  to Executive an additional lump sum (hereafter "Additional
                  Pay") equal to Executive's then current base compensation for
                  a period of one (1) year commencing on the day of Executive's
                  termination. Any non-renewable of this Agreement, for any
                  reason, shall be deemed to be without cause.

      All such payments will be made by Company within 30 days of the
      termination date. Upon termination, Executive will have no rights to any
      unvested benefits or any other compensation or payments except as stated
      in this paragraph.

      6.    TERMINATION BY EXECUTIVE. Executive may terminate Executive's
            engagement under this Agreement for any reason provided that
            Executive gives Company at least thirty (30) days' notice in
            writing. Company may, at its option, accelerate such termination
            date to any at least two weeks after Executive's notice of
            termination. Company may, at its option,

                                                                               3

<PAGE>

            relieve Executive of all duties and authority after notice of
            termination has been provided. All compensation, payments and
            unvested benefits will cease after the termination date.

      7.    TERMINATION UPON COMPANY REORGANIZATION, MERGER OR SALE.
            Notwithstanding Section 5.1 and 5.2 of this Agreement, in the event
            Executive's engagement is terminated for any reason, including
            resignation of Executive or non-renewal of this Agreement, but
            excluding termination of cause, during the one (1) year period
            following the effective date of: (1) a consolidation or merger of
            the Company with another corporation or entity; (2) the sale to a
            third party of stock of the Company which, when issued and outstand,
            will constitute more than 50% of the issued and outstanding stock of
            the Company; (3) the sale of all or substantially all of the assets
            of the Company to a third party; or (4) the liquidation,
            dissolution, reorganization or commencement of any proceeding under
            federal or state bankruptcy or insolvency laws by the Company, the
            Company will pay Executive all earned but unpaid base cash
            compensation (prorated to the date of such termination), all accrued
            but unused vacation time, and any not yet reimbursed business
            expenses incurred for services provided through the date of
            termination. Company will pay the Executive, the amount of one
            million Dollars ($1,000,000). The payments made pursuant to this
            Section 7 shall be in lieu of payments provided for in Section 5.1
            or Section 5.2.

                  In addition, upon termination of Executive's engagement with
            Company pursuant to this Section 7, Executive will be entitled to
            the following (hereafter "Additional Section 7"): (1) within thirty
            (30) calendar days of termination pursuant of this Section 7 herein,
            a sum equal to Executive's then-current base cash compensation for a
            period of two (2) years; (2) all stock options grants to Executive,
            if any, granted pursuant to any stock option agreement will become
            immediately vested and exercisable.

            Company agrees to request any successors or successors to all or
            substantially all of the business and/or assets of Company (whether
            direct or indirect, by purchase, merger, consolidation, liquidation
            or otherwise), upon or prior to such succession, to expressly assume
            and agree to perform this Agreement in the same manner and to the
            same extent that Company would be required to perform it if no such
            succession had taken place. A copy of such assumption and agreement
            will be delivered to Executive promptly after its execution by the
            successor. Failure by Company to obtain such agreement from
            successors on or before the effective date of any such succession
            transaction shall entitle Executive to such benefits and pay the
            Company in the same amounts as Executive would be entitled in
            Section 7 herein as if Executive had been terminated without cause
            of the day prior to the effective date of such transaction

                                                                               4

<PAGE>

            upon termination. Any assumption by a third-party of the Company's
            obligation under this Agreement shall not release Company from its
            obligations under this Agreement.

      8.    COVENANT NOT TO COMPETE. During Executive's engagement by Company
            and for a period expiring one (1) year after the termination of
            Executive's engagement for any reason, Executive covenants and
            agrees that Executive will not:

            8.1   Directly, indirectly, or otherwise, own, manage, operate,
                  control, serve as a consultant to, be employed by, participate
                  in, or be connected, in any manner, without the ownership,
                  management, operation or control of any business that uses
                  chemokines as therapeutic drugs.

            8.2   Here, off to hire, entice away or in any other manner persuade
                  or attempt to persuade any office, Executive or agent of
                  Company to alter or discontinue a relationship with Company or
                  to any act that is inconsistent with the interests of Company;

            8.3   Except on behalf of Company, directly or indirectly solicit,
                  divert, take away or attempt to solicit, divert or take away
                  any customers of Company; or

            8.4   Except on behalf of Company, directly or indirectly solicit,
                  divert, or in any other manner persuade or attempt to persuade
                  any supplier of Company to alter or discontinue its
                  relationship with Company.

      For the purposes of this Section 8, businesses that are deemed to compete
      with Company's Business are business that are engaged in the research and
      development of Chemokine agonists and antagonists in the treatment of
      cancer or for the purpose of stem cell mobilization, neutrophils
      mobilization or platelets mobilization. Further, the use of chemokines
      agonists or antagonists in the growth and stimulation of stem cells or
      white blood cells. Executive can own or manage/consult business that are
      not involved in chemokines.

            Company and Executive agree that: this provision does not impose an
      undue hardship on Executive and is not injurious to the public; that this
      provision is necessary to protect the business of Company; the nature of
      Executive's responsibilities with Company under this Agreement require
      Executive to have access to confidential information which is valuable and
      confidential to all of the Business; the scope of this Section 8 is
      reasonable in terms of length of time and geographic scope; and adequate
      consideration supports this Section 8, including consideration herein.

                                                                               5

<PAGE>

      9. CONFIDENTIAL INFORMATION. Executive recognizes that Company's Business
      and continued success depend upon the use and protection of confidential
      and propriety business information, including, without limitation, the
      information and technology developed by or available through licenses to
      Company related to the Company's Business, to which Executive has access
      (all such information being "Confidential Information"). For purposes of
      this Agreement, the phrase "Confidential Information" includes for Company
      and its current or future subsidiaries and affiliates, without limitation,
      and whether or not specifically designated as confidential or proprietary:
      all business plans and marketing strategies; information concerning the
      development of new products and services; and technical and non-technical
      data related to software programs, designs, specifications, compilations,
      inventions, improvements, methods, processes, procedures and techniques;
      provided, however, that the phrase does not include information that (a)
      was lawfully in Executive's possession prior to disclosure of such
      information by Company; (b) was, or at any time becomes, available in the
      public domain other than through a violation of this Agreement; (c) is
      documented by Executive as having been developed by Executive outside the
      scope of Executive's engagement and independently; or (d) is furnished to
      Executive by a third party not under an obligation of confidentiality or
      Company. Executive agrees that during Executive's engagement and after
      termination of the Agreement irrespective of cause, Executive will use
      Confidential Information only for the benefit of Company and will not
      directly or indirectly use or divulge, any Confidential Information for
      any reason, except as authorized by Company. For the purpose of this
      agreement, the Confidential Information means, the use of chemokines in
      the treatment of cancer and the use of chemokines in haematology.
      Executive agrees to deliver to Company immediately upon termination of
      Executive's engagement, or at any time Company so requests, all tangible
      items containing any Confidential Information (including, without
      limitation, all memoranda, photographs, records, reports, manuals,
      drawings, blueprints, prototypes, notes taken by or provided to Executive,
      and any other documents or items of a confidential belonging to Company),
      together with all copies of such material in Executive's possession or
      control. Executive agrees that in the course of Executive engagement with
      Company, Executive will not violate in any way the rights that any entity
      has with regard to trade secrets or proprietary or confidential
      information. Executive's obligations under this Section 8 are indefinite
      in term and shall survive the termination of this Agreement.

      10. INVENTIONS, IDEAS, PATENTS AND COPYRIGHTS

            10.1 DISCLOSURE AND ASSIGNMENT OF INVENTIONS AND WORKS. "Inventions"
      means all discoveries, improvements and ideas, whether patentable or not
      in the filed of chemokines, conceived or made by Executive, solely or
      jointly with others, at any time during Executive's engagement by Company
      or within three

                                                                               6

<PAGE>

      months after Executive's engagement by Company, including, but not limited
      to, any formulas, methods, techniques, devices, equipment, products,
      product development and engineering, research, processes, and marketing
      programs. "Works" means all tangible work product, whether patentable or
      copyrightable or not, developed or under development by Executive, solely
      or jointly with others, at any time during Executive's engagement by
      Company or within three months after Executive's engagement by Company or
      within three months after specifications, compilations, programs,
      documentation, manuals, flow charts, diagrams, drawings, photographs,
      designs, business or marketing plans, articles for publication, contracts,
      and reports. Executive shall promptly disclose to Company all inventions
      or works pertain to chemokine biology, whether made or developed during
      Executive's normal working hours. Executive will keep and maintain written
      records concerting such Inventions and Works and make these records
      available to Company to all times. Company shall hold such written records
      with the same degree of care as it does other business documents of a
      confidential nature. Subject to the limitations started in Section 10.3,
      Executive acknowledges and agrees that all Chemokine related technology,
      Executive shall have no proprietary interest in Inventions and Works and
      that Inventions are the sole and exclusive property of Company, and
      Executive hereby irrevocably assigns and agrees to assign to Company and
      its successors, assigns or nominees all right, title and interest of
      Executive in the Inventions worldwide on chemokine. Executive agrees that
      the Works are to be deemed "works-made-for-hire," and that Company shall
      be deemed the author and, subject to the limitations stated in Section
      10.3 Company shall own all proprietary rights in the Works and have the
      right to obtain and hold in its own name all trademarks, copyrights,
      registrations, or such other protection as may be appropriate to the
      subject matter, and any extensions and renewals thereof. To the extent
      that title to the Works may not, by operation of law, vest in Company or
      that Works may not be considered "work-made-for-hire," subject to the
      limitations started in Section 10.3, Executive hereby irrevocably assigns
      and agrees to assign to Company and its successors, assigns or nominees
      all right, title and interest of Executive in the chemokine science
      worldwide.

            10.2 LICENSE. If and to the extent that Executive makes use, or has
made use, in the course of Executive's engagement by Company, of any
intellectual properties owned by Executive in the filed of chemokines, Executive
hereby grants to Company a nonexclusive, royalty-free, perpetual, irrevocable,
worldwide license (with right to sublicense) to make, use, sell, offer for sale,
copy, distribute, import, modify, and other to practice and exploit any and all
such intellectual properties. In the course of Executive's engagement by
Company, Executive shall not use or induce Company to use any information that
infringes any patent, trademarks, copyright, trade secret or other proprietary
rights of others and shall not disclose to Company or induce Company to use any
secrecy or confidential information of others, including former company, to whom
Executive has obligations of secrecy.

            10.3 EXCLUDED INVENTIONS. Executive has been given the opportunity
to prepare and attach hereto a list of all inventions, patent applications and
patents made

                                                                               7

<PAGE>

or conceived by Executive prior to the date of Executive's engagement by
Company, which are subject to prior agreements or which Executive desires to
exclude from the Agreement. If no such list is attached, Executive hereby
represents and warrants to Company that there are no such inventions, patent
applications or parents. Additionally, Executive understands and acknowledges
having been given notice herein that, in accordance with Company's policy and
British Columbia (BC) law, this Agreement does not apply to, and that Executive
shall have no obligation to assign to Company, any Invention or Works for which
no Company trade secrets and no equipment, supplies, or facilities of Company
were used and which as developed entirely on Executive's own time, unless: (i)
the Invention or Works relate directly to the business of Company (i.e.
Chemokine), (ii) the Invention or Works relate to actual or demonstrably
anticipated research or development work of Company, or (iii) the Invention or
Works result from any work performed by Executive for Company.

11.   REMEDIES. Notwithstanding other provisions of this Agreement regarding
      dispute resolution, Executive agrees that Executive's violent of any of
      Sections 8 or 9 of this Agreement would cause Company irreparable harm
      which would not be adequately compensated by monetary damages and that an
      injunction may be granted by any court or courts having jurisdiction,
      restraining Executive from violation of the terms of this Agreement, upon
      any breach or threatened breach of Executive of the obligations set forth
      in any of Section 8,9 or 10. The preceding sentence shall not be construed
      to limit Company from any other relief or damages to which it may be
      entitled as a result of Executive's breach of any provision of this
      Agreement, including Section 8 or 9. Executive also agrees that a violent
      of any of Section 8, 9 or 10 would entitle Company, in addition to all
      other remedies available at law or equity, to recover from Executive any
      and all funds, including, without limitation, wages and compensation,
      which will be held by Executive in constructive trust for Company,
      received by Executive in connection with such violation.

12.   DISPUTE RESOLUTION. Except for the right of Company and Executives to seek
      injunctive relief in court and to the fullest extent permitted by law, any
      controversy, claim or dispute of any type arising out of or relating to
      Executive's engagement or the provisions of this Agreement shall be
      resolved in accordance with this Section 12 regarding resolution of
      disputes, which will be the sole and exclusive procedure for the
      resolution of any disputes. Matters subject to these provisions include,
      without limitation, claims or disputes based on statute, contract, common
      law and tort and will include, for example, matters pertaining to
      termination, discrimination, harassment, compensation and benefits.
      Nothing in this provision is intended to restrict Executive from
      submitting any matter to an administrative agency with jurisdiction over
      such matter.

            12.1  COMPLIANCE WITH COMPANY POLICY. Executive and Company will
                  make a good faith attempt to resolve all disputes in
                  accordance with any dispute resolution policy adopted by
                  Company before resorting to any other dispute resolution
                  procedure.

                                                                               8

<PAGE>

            12.2  ARBITRATION. If any claim or dispute has not been resolved in
                  accordance with Section 12.1 and Section 12.2, then the claim
                  or dispute will be determined by arbitration in Vancouver, BC,
                  in accordance with the then-current national rules for the
                  resolution of engagement disputes by arbitration, except as
                  modified herein. The arbitration will be conducted by a sole
                  neutral arbitrator who has had both training and experience as
                  an arbitrator of general engagement and commercial matters and
                  who is and for at least ten (10) years has been, a partner, a
                  shareholder, or a member in a law firm. If Company and
                  Executive cannot agree on an arbitrator, then the arbitrator
                  will be selected by the judge applying the criteria in this
                  provision.

                  No person who has served as a mediator under the mediation
                  provision, however, may be selected as the arbitrator for the
                  same claim or dispute. Reasonable discovery will be permitted
                  and the arbitrator may decide any issues as to discovery. The
                  arbitrator may decide any issues as to whether or as to the
                  extent to which, any dispute is subject to the dispute
                  resolution provisions in Section 12 and the arbitrator may
                  award any relief permitted by law. The arbitrator must base
                  the arbitrator award on the provisions of Section 11 and
                  applicable law and must render the award in writing, including
                  an explanation of the reasons for the award. Judgment upon the
                  award may be entered by any court having jurisdiction of the
                  matter, and the decision of the arbitrator will be final and
                  binding.

                  The statute of limitations applicable to the commencement of a
                  lawsuit will apply to the commencement of an arbitration under
                  Section 12.2.

      13.   FEES. Unless otherwise agreed, the prevailing party will be entitled
            to its costs and attorneys' fees incurred in any litigation relating
            to the interpretation or enforcement of this Agreement.

      14.   DISCLOSURE. Executive agrees fully and completely to reveal the
            terms of this Agreement to any future Company or potential Company
            of Executive and authorizes Company, at its election, to make such
            disclosure.

      15.   REPRESENTATION OF EXECUTIVE. Executive represents and warrants to
            Company that Executive is free to enter into this Agreement and has
            no commitment, arrangement or understand to or with any party that
            restrains

                                                                               9

<PAGE>

            or is in conflict with Executive's performance of the covenants,
            services and duties provided for in this Agreement.

            Executive agrees to indemnify Company and to hold it harmless
            against any and all liabilities or claims arising out of any
            unauthorized act or acts by Executive that, the foregoing
            representation and warranty to the contrary notwithstanding, and in
            violation, or constitute a breach, of any such commitment,
            arrangement or understanding.

      16.   ASSIGNABILITY. During Executive's engagement, this Agreement may not
            be assigned by either party without the written consent of the
            other; provided, however, that Company may assign its rights and
            obligations under this Agreement without Executive's consent
            pursuant to a successor by sae, merger or liquidation, if such
            successor carries on the Company's Business substantially in the
            form in which it is being conducted at the time of the sale, merger
            or liquidation.

            This Agreement is binding upon Executive, Executive's heirs,
            personal representatives and permitted assigns and on Company, its
            successors and assigns.

      17.   NOTICES. Any notice required or permitted to be given hereunder are
            sufficient if in writing and delivered by hand, by facsimile or by
            registered or certified mail, to Executive at 927 Pacific Drive,
            Delta, BC, V4M 2K2 or such other address as may be provided by
            Executive.

      18.   SEVERABILITY. If any provision of this Agreement or compliance by
            any of the parties with any provision of this Agreement constitutes
            a violation of any law, or is or becomes unenforceable or void, then
            such provision, to the extent necessary so that it is no longer in
            violation of law, unenforceable or void, and such provision will be
            enforced to the fullest extent permitted by law. If such
            modification is not possible, said provision, to the extent that it
            is in violation of law, unenforceable or void, shall be deemed sever
            able from the remaining provisions of this Agreement, which
            provisions will remain binding on the parties.

      19.   WAIVERS. No failure on the part of either party to exercise, and no
            delay in exercising, any right or remedy hereunder will operate as a
            waiver thereof; nor will any single or partial waiver of a breach of
            any provision of this Agreement operate or be construe as a waiver
            of any subsequent breach; nor will any single or partial exercise of
            any right or remedy hereunder

                                                                              10

<PAGE>

            preclude any other further exercise thereof or the exercise of any
            other right or remedy granted hereby or by law.

      20.   GOVERNING LAW. The validity, constructions and performance of this
            Agreement shall be governed by the laws of the Province of British
            Columbia without regard to the conflicts of law provisions of such
            laws.

            The parties hereto expressly recognize and agree that the
            implementation of the Section 19 in essential in light of the fact
            that Company has its corporate headquarters and its principal
            executive offices within the Province of British Columbia, and there
            is a critical need for uniformity in the interpretation and
            enforcement of the engagement agreements between Company an its key
            Executives.

      21.   CHANGE OF DUTY. Executive may at its sole decision accept the change
            in title and duty, acceptable to the Company. Upon the change of
            duty and title, the Company shall continue to provide the Executive
            with the sale financials compensation, and stock options as
            otherwise would have received under the position of Chairman,
            President and CEO.

      22.   SURVIVAL. Notwithstanding the provisions of Paragraphs 5, 6 or 7,
            the provisions of Paragraphs 8, 9, 10, 11, 12, 13, 14, 15, 16, 17,
            18, 19 and 20 shall survive the termination of this Agreement.

      23.   ENTIRE AGREEMENT. This instrument contains the entire agreement of
            the parties with respect to the relationship between Executive and
            the Company and supersedes all prior agreements and understandings,
            and there are no other representations or agreements other than as
            stated in this Agreement related to the terms and conditions of
            Executive's engagement.

            This Agreement may be changed only by an agreement in writing signed
            by the party against whom enforcement of any waver, change,
            modification, extension or discharge is sought, and any such
            modification will be signed by the CEO of the Company.

                                                                              11

<PAGE>

IN THE WITNESS WHEREOF, the parties have duly signed and delivered this
Agreement as of the day and year first above written.

COMPANY

CHEMOKINE THERAPEUTICS CORP

________________________________________________
On behalf of the Board of Directors
Name: Richard Piazza, Director, Chair of Executive Compensation Committee

EXECUTIVE (Employee)

________________________________________________
Dr. Hassan Salari
Chairman, President &CEO

                                                                              12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00069-of-00352.parquet"}]]